Skip to Main Content

Paper Details

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.
Ann Oncol
34
2021
Author NameAffiliation
Matti AnnalaUniversity of British Columbia, Tampere University and Tays Cancer Centre
Sinja TaavitsainenTampere University and Tays Cancer Centre
Matti NykterTampere University and Tays Cancer Centre
Arun A AzadPeter MacCallum Cancer Centre
Alexander W WyattUniversity of British Columbia
Kim N ChiUniversity of British Columbia
  • 1 - 6

Datasets

Release 1.2